Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine L Baker

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|February 7, 2018
A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trialChristine L Baker, Guilhem Pietri
Journal of Medical Economics|January 30, 2018
Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic frameworkMark P Connolly, Christine L Baker, Nikolaos Kotsopoulos
International Journal of Chronic Obstructive Pulmonary Disease|December 19, 2013
Risk assessment of readmissions following an initial COPD-related hospitalizationChristine L Baker, Kelly H Zou, Jun Su
International Journal of Chronic Obstructive Pulmonary Disease|May 17, 2014
Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims dataChristine L Baker, Kelly H Zou, Jun Su
The Journal of Molecular Diagnostics : JMD|October 27, 2011
A PIK3CA pyrosequencing-based assay that excludes pseudogene interferenceChristine L Baker, Cecily P Vaughn, Wade S Samowitz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 17, 2009
The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO modelChris Knight, Paul Howard, Christine L Baker, et al.
Advances in Therapy|November 27, 2016
Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare PayersChristine L Baker, Cheryl P Ferrufino, Marianna Bruno, et al.
Psychopharmacology|December 18, 2007
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attemptRobert West, Christine L Baker, Joseph C Cappelleri, et al.
BMC Public Health|June 25, 2010
Recent trends in exposure to secondhand smoke in the United States populationChieh-I Chen, Tanya Burton, Christine L Baker, et al.
Journal of Medical Economics|July 9, 2010
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidenceJosephine A Mauskopf, Christine L Baker, Brigitta U Monz, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Clinicoeconomics and Outcomes Research : CEOR|February 7, 2018
A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trialChristine L Baker, Guilhem Pietri
Journal of Medical Economics|January 30, 2018
Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic frameworkMark P Connolly, Christine L Baker, Nikolaos Kotsopoulos
International Journal of Chronic Obstructive Pulmonary Disease|December 19, 2013
Risk assessment of readmissions following an initial COPD-related hospitalizationChristine L Baker, Kelly H Zou, Jun Su
International Journal of Chronic Obstructive Pulmonary Disease|May 17, 2014
Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims dataChristine L Baker, Kelly H Zou, Jun Su
The Journal of Molecular Diagnostics : JMD|October 27, 2011
A PIK3CA pyrosequencing-based assay that excludes pseudogene interferenceChristine L Baker, Cecily P Vaughn, Wade S Samowitz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 17, 2009
The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO modelChris Knight, Paul Howard, Christine L Baker, et al.
Advances in Therapy|November 27, 2016
Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare PayersChristine L Baker, Cheryl P Ferrufino, Marianna Bruno, et al.
Psychopharmacology|December 18, 2007
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attemptRobert West, Christine L Baker, Joseph C Cappelleri, et al.
BMC Public Health|June 25, 2010
Recent trends in exposure to secondhand smoke in the United States populationChieh-I Chen, Tanya Burton, Christine L Baker, et al.
Journal of Medical Economics|July 9, 2010
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidenceJosephine A Mauskopf, Christine L Baker, Brigitta U Monz, et al.
Pageof 5